Cardiology

Data from an ongoing, prospective study conducted in multiple countries provides an overview of characteristics and outcomes among patients with type 2 myocardial infarction.

Clinical decision support intervention resulted in a rate of change in total modifiable CV risk that was 4% lower among intervention patients compared to control.

With the FDA approval announced by Cordis on March 10, the company is hopeful the S.M.A.R.T. RADIANZ Vascular Stent System can help optimize radial access and improve patient outcomes.

Patients with tachyarrhythmia or hypertension as their underlying trigger of type 2 MI had a lower mortality than patients with hypotension, hypoxemia, or anemia.

On March 8, the American College of Rheumatology and the Vasculitis Foundation released new guidance for diagnosis and management of Kawasaki disease, which serves as the final companion piece to a trio of other ACR/VF vasculitis guidelines released in July 2021.

In the most recent episode of Don't Miss a Beat, co-hosts Drs. Vaduganathan and Greene are joined by Dr. Eugene Braunwald for a conversation that touches on the founding of the TIMI Study Group, the evolution of clinical trials, and advice he would give to early career professionals with an interest in becoming trialists.

A look into the uptake of semaglutide, what the agent represents, and what is coming further in obesity management.

Levels of troponin after cardiac surgery associated with increased risk of death were higher than levels recommended to define periprocedural myocardial injury.

The heart transplant from a genetically modified pig was initially considered a success and represented new hope for Americans requiring transplants.

New research from the US CDC's COVID-19 Response Team details the increased risks of severe COVID-19 infection associated with congenital heart defects.

Dr. Granger discusses the current underuse of these agents and the steps cardiologists need to take to increase prescription rates and uptake for patients.

Dr. Pagidipati highlights her own approach to weight management, from lifestyle changes, diet, and medication to metabolic procedures.

Data from the VITAL-AF trial indicate universal screening with single-lead ECGs among patients 65 years and older in primary care settings did not significantly increase in new atrial fibrillation diagnoses, but was more effective in patients aged 85 years or older.

The University of Colorado expert joins for a 5-part interview on making sense of the boom of new agents and care strategies.

The Yale Associate Chief of Cardiovascular Medicine discusses improved use of available drug classes, as well as the potential approval for omecamtiv mecarbil.

From a couple of novel heart failure treatments to a promising dual receptor agonist, here's a rundown of expected pipeline news this year in heart disease.

Results of the VISION Cardiac Surgery study indicate measurements of hs-TnI the first day after surgery could provide insight into the risk of mortality in the first 30 days after cardiac surgery.

The Johns Hopkins expert details recent advances in remote cardiovascular care and research, and explains how the field will continue to evolve.

The absolute survival rate observed for US patients with IHCA and COVID-19 was 11.9%.

Our latest case report from Brady Pregerson, MD, features a woman in her mid-80s with a history of breast cancer presenting to the hospital with a burning sensation in her chest for the past 3 days she describes as feeling like indigestion. Can you determine the correct diagnosis?

A review of data from the prospective SmartCare-CAD trial details the primary drivers of nonparticipation in telerehabilitation programs among patients with cardiovascular conditions.

The complete response letter from the FDA cited a lack of effectiveness in slowing the loss of kidney function in patients with Alport syndrome.

The CRL for bardoxolone methyl for treatment of CKD caused by Alport syndrome comes less than 3 months after an FDA advisory committee voted unanimously against approval of Reata Pharmaceutical's once-daily, orally administered activator of Nrf2.

In this section of our Disease State Series, readers will find a list of resources curated by our editorial staff with the help of key opinion leaders to provide insight into management of heart failure for primary care providers.